Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

Study links thymus radiation to worse lung cancer outcomes

Until recently, the thymus was thought to be of little use beyond puberty, but new research has shown that radiation to the organ is associated with worse outcomes in patients being treated for non-small cell lung cancer (NSCLC).

25 Aug 2026

Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation

Several cannabinoids reduced chemotherapy- and radiation-induced apoptosis in glioblastoma cell models, with effects linked to reduced apoptotic priming, increased pro-survival signaling, and G1 cell-cycle arrest. The findings raise concern that cannabinoid exposure could interfere with some cancer treatments, although the results are limited to laboratory models and require in vivo and clinical validation.

12 Aug 2026

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients

Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients with advanced stage or recurrent endometrial cancer when compared to chemotherapy alone.

29 May 2026

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.

29 May 2026

Letrozole monotherapy falls short in ovarian cancer clinical trial

Late breaking results from the phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate non inferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression free survival (PFS) in patients with newly diagnosed stage II-IV low grade serous carcinoma of the ovary or peritoneum.

11 Apr 2026

Clinical trial aims to improve survival for patients with recurrent head and neck cancer

A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients whose disease returns after radiation therapy – a setback that affects up to 40% of patients and is often associated with poor outcomes.

27 Jan 2026

Chemotherapy may reduce HIV-infected T cells

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at undetectable levels and nontransmissible as long as therapy is maintained.

15 Dec 2025

Innovative CRISPR strategy resensitizes lung cancer to treatment

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer.

17 Nov 2025

Study offers new models for understanding the causes of chemo brain

Cancer is a challenging enough diagnosis, but many patients are dealt a second blow, even as they heal: "chemo brain."

13 Oct 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

Combination treatment approach shows promise for hard-to-treat triple-negative breast cancer

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease progression in patients with advanced triple-negative breast cancer (TNBC), one of the most aggressive and hard-to-treat forms of breast cancer.

21 Aug 2025

New formulation of chemotherapy drug opens doors to advanced cancer treatment options

University of Arizona researchers devised a new method to deliver cancer chemotherapy drugs to pancreatic and breast cancer tumors more effectively and with less damage to healthy tissues than standard forms of chemotherapy.

21 Aug 2025

Starfish compound overcomes drug resistance in prostate cancer models

Researchers identified that triterpene glycosides from the starfish Solaster pacificus can kill drug-resistant prostate cancer cells in vitro by bypassing common resistance pathways. CuC1 showed synergy with existing chemotherapies, though with only moderate selectivity for cancer cells.

5 Aug 2025

Scientists reveal how chemotherapy causes genetic damage in healthy blood

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.

2 Jul 2025

New DNA test predicts chemotherapy resistance in cancer patients

Cancer Research UK-funded scientists at the University of Cambridge, in collaboration with the Spanish National Cancer Research Centre (CNIO) and Cambridge-based startup Tailor Bio, have created a test which can successfully predict whether cancer will resist common forms of chemotherapy treatment.

23 Jun 2025

Enfortumab vedotin and pembrolizumab show major benefits for urothelial carcinoma patients

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, urothelial carcinomas grow in the bladder (bladder carcinoma).

4 Apr 2025

New treatment option for advanced thymic carcinoma shows promise

Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma.

12 Mar 2025

Carboplatin News and Research

Further Reading

Study links thymus radiation to worse lung cancer outcomes

Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

Letrozole monotherapy falls short in ovarian cancer clinical trial

Clinical trial aims to improve survival for patients with recurrent head and neck cancer

Chemotherapy may reduce HIV-infected T cells

Innovative CRISPR strategy resensitizes lung cancer to treatment

Study offers new models for understanding the causes of chemo brain

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Combination treatment approach shows promise for hard-to-treat triple-negative breast cancer

New formulation of chemotherapy drug opens doors to advanced cancer treatment options

Starfish compound overcomes drug resistance in prostate cancer models

Scientists reveal how chemotherapy causes genetic damage in healthy blood

New DNA test predicts chemotherapy resistance in cancer patients

Enfortumab vedotin and pembrolizumab show major benefits for urothelial carcinoma patients

New treatment option for advanced thymic carcinoma shows promise

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News